English 
Japanese 
Latest news
- November 20, 2025Recent Choices for PPI Detection for Experimental Confirmation
- November 18, 2025Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
- November 14, 2025PRISM BioLab Announces Achievement of Initial Milestone and Receipt of Upfront Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
- November 6, 2025PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical
- November 6, 2025Molecular chameleons: Oral Absorption Analysis in Middle-Sized Molecules
Latest News
- Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
- PRISM BioLab Announces Achievement of Initial Milestone and Receipt of Upfront Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
- PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical
- Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress
- PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
- Notice of Termination of Collaboration and Licensing Agreement with Servier
- Notice of Termination of Collaboration and Licensing Agreement with Eli Lilly and Company
- PRISM BioLab Announces Patent Acquisition for PepMetics® Technology Library Compounds
- Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
- Announcement: Investor Relations Seminar for Individual Investors
About
PRISM BIOLAB
MISSION:
PRISM BioLab is committed to maximizing the potential of its PepMetics® Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.
PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.
PepMetics
Technology
We synthesize like a small molecule, but our PepMetic Molecules act like peptides.
Peptide
MIMETICS
“PepMetics”®
LIBRARY
PRISM’s PepMetics Real Library includes 20,000+ compounds covering various amino acid sequences for screening. The PepMetics Library is used to generate hits for difficult targets.
